AG-490 (Tyrphostin B42)

Name: AG-490 (Tyrphostin B42)
Brand: Selleck Chemicals
SKU: S1143
Rating: 5 (103 reviews)

For research use only.

Catalog No.S1143 Synonyms: Zinc02557947

103 publications

AG-490 (Tyrphostin B42) Chemical Structure

CAS No. 133550-30-8

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

Selleck's AG-490 (Tyrphostin B42) has been cited by 103 publications

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Front Nutr, 2021, 8:649640

PubMed: 33869267 ( click the link to review the publication )

Oncol Rep, 2021, 10.3892/or.2021.7926

PubMed: 33432366 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(18):18084-18098

PubMed: 32957082 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Oncogenesis, 2020, 10;9(2):15

PubMed: 32041943 ( click the link to review the publication )

Front Pharmacol, 2020, 26;11:273

PubMed: 32273843 ( click the link to review the publication )

J Neurodev Disord, 2020, 12(1):29

PubMed: 33172406 ( click the link to review the publication )

Food Funct, 2020, 11(5):3941-3951

PubMed: 32338270 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):632

PubMed: 32641093 ( click the link to review the publication )

Mol Cells, 2020, 43(8):749-762

PubMed: 32868491 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

J Appl Toxicol, 2020, 24

PubMed: 32212198 ( click the link to review the publication )

Connect Tissue Res, 2020, 5;1-16

PubMed: 32370570 ( click the link to review the publication )

J Interferon Cytokine Res, 2020, 40(2):116-124

PubMed: 31834821 ( click the link to review the publication )

Int J Med Sci, 2020, 17(18):3174-3189

PubMed: 33173437 ( click the link to review the publication )

Pharmazie, 2020, 75(6):255-260

PubMed: 32539921 ( click the link to review the publication )

Arch Biochem Biophys, 2020, 685:108330

PubMed: 32156533 ( click the link to review the publication )

Cell Prolif, 2020, 53(8):e12856

PubMed: 32648622 ( click the link to review the publication )

Mol Med Rep, 2020, 21(1):89-96

PubMed: 31746349 ( click the link to review the publication )

Virus Res, 2020, 281:197907

PubMed: 32113834 ( click the link to review the publication )

J Cancer, 2020, 11(16):4771-4782

PubMed: 32626524 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):360-367

PubMed: 31668806 ( click the link to review the publication )
Oxid Med Cell Longev, 2020, 2020:9187406

PubMed: 32832009 ( click the link to review the publication )

J Surg Res, 2020, 248:98-108

PubMed: 31877436 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):963-969

PubMed: 32059851 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(17):6674-6690

PubMed: 31481647 ( click the link to review the publication )

J Cell Physiol, 2019, 234(9):15395-15406

PubMed: 30710340 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21182-21192

PubMed: 31032948 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(9):1882-1891

PubMed: 31523190 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:57

PubMed: 30918473 ( click the link to review the publication )

Front Pharmacol, 2019, 10:620

PubMed: 31231218 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Eur J Pharmacol, 2019, 854:289-297

PubMed: 31004602 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9069-9076

PubMed: 31802914 ( click the link to review the publication )

Oral Dis, 2019, 25(7):1769-1779

PubMed: 31365165 ( click the link to review the publication )

Can Respir J, 2019, 2019:2697376

PubMed: 31379980 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

J Cell Physiol, 2018, 234(1):454-463

PubMed: 29932210 ( click the link to review the publication )

Mol Carcinog, 2018, 57(3):429-439

PubMed: 29215754 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:107-114

PubMed: 29477470 ( click the link to review the publication )

Int J Oncol, 2018, 52(5):1515-1527

PubMed: 29512698 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(2):465-473

PubMed: 29511440 ( click the link to review the publication )
Eur J Pharmacol, 2018, 833:221-229

PubMed: 29890157 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Biomed Res Int, 2018, 2018:2548378

PubMed: 30363706 ( click the link to review the publication )

Neurosci Lett, 2018, 662:219-226

PubMed: 29061394 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):2517-2524

PubMed: 30013646 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(8):1535-1544

PubMed: 29508174 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(5):251-268

PubMed: 27923278 ( click the link to review the publication )

Cardiovasc Res, 2017, 113(3):310-320

PubMed: 28158495 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 44(1):293-302

PubMed: 29132131 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(12)

PubMed: 29206176 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4617-4626

PubMed: 29118922 ( click the link to review the publication )

Brain Res, 2017, 15;1657:202-207

PubMed: 27998796 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:2787-2799

PubMed: 29033541 ( click the link to review the publication )

Biosci Rep, 2017, 37(6)BSR20171038

PubMed: 29074558 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169665

PubMed: 28068414 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5329-5336

PubMed: 29184419 ( click the link to review the publication )

Cell Biol Int, 2017, 41(6):659-668

PubMed: 28378938 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:2942830

PubMed: 28630633 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96993-97008

PubMed: 29228588 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96958-96969

PubMed: 29228585 ( click the link to review the publication )

Oncotarget, 2017, 8(39):64853-64866

PubMed: 29029396 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45848-45861

PubMed: 28507278 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005605

PubMed: 27128969 ( click the link to review the publication )
Oncoimmunology, 2016, 5(12):e1252012

PubMed: 28123894 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(7):960-9

PubMed: 27130223 ( click the link to review the publication )

Sci Rep, 2016, 6:33676

PubMed: 27633396 ( click the link to review the publication )

Clin Exp Immunol, 2016, 184(2):147-58

PubMed: 26646950 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

J Bone Miner Metab, 2016, [Epub ahead of print]

PubMed: 27628046 ( click the link to review the publication )

Scand J Immunol, 2016,

PubMed: 26482544 ( click the link to review the publication )

Mol Med Rep, 2016, 13(4):3684-90

PubMed: 26936086 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41445-41459

PubMed: 27213590 ( click the link to review the publication )

J Am Soc Nephrol, 2016, 27(10):3105-3116

PubMed: 27694161 ( click the link to review the publication )

Cancer Lett, 2015, 359(2):335-43

PubMed: 25641338 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: 25411359 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1287-99

PubMed: 25979764 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.020

PubMed: ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 19(2)

PubMed: 26438799 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

J Geriatr Cardiol, 2015, 12(6):591-9

PubMed: 26788034 ( click the link to review the publication )

Mol Cancer, 2014, 13:176

PubMed: 25047660 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2014, 307(7):C597-605

PubMed: 24944200 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7051-64

PubMed: 25216522 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(17):4697-705

PubMed: 23857601 ( click the link to review the publication )

Cancer Lett, 2013, 341(2):224-30

PubMed: 23941832 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):533-9

PubMed: 23665018 ( click the link to review the publication )

Prostate, 2012, 73(3):267-77

PubMed: 22821817 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

JAK2 (V617F) ^[8] ()	EGFR ^[1] (Cell-free assay)
	0.1 μM

In vitro

AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. ^[1] Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. ^[2] AG-490 (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. ^[3] AG-490 potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. ^[4] Although AG-490 alone has no effect on proliferation of FDrv210H cells at a concentration of 5 μM, AG-490 can synergize with STI571 to enhance its inhibitory effect on p210^bcr-abl driven proliferation. ^[5] AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. ^[6] AG-490 (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. ^[7] AG-490 at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. AG-490 also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. ^[8]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BC3	MVHGeY5kfGmxbjDBd5NigQ>?	M4rWT\|ExOOLCidM1US=>	MmrkNlQhcA>?		NWC4bYpwdWWmaXH0[ZMhWEWOIHPlcIwh[XCxcITvd4l{	MUiyOlE5PDl7OR?=
BCBL1	MVLGeY5kfGmxbjDBd5NigQ>?	MlnENVAx6oDLwsXN	MlzFNlQhcA>?		NUDoc3dRdWWmaXH0[ZMhWEWOIHPlcIwh[XCxcITvd4l{	NGDLUlAzPjF6NEm5PS=>
BC3	NGnaT3BHfW6ldHnvckBCe3OjeR?=	NIPpfXAyODEkgJpCuW0>	M3HEbVI1KGh?		Mnj6cYVlcWG2ZYOg[IUueGixc4Doc5J6dGG2aX;uJI9nKFOWQWSzJINwenKnbHH0[YQhf2m2aDDIV3A4OCCjbnSgTHNHOSC{ZXT1Z5Rqd25?	MofMNlYyQDR7OUm=
BCBL1	MkTuSpVv[3Srb36gRZN{[Xl?	M2DvZlExOOLCidM1US=>	MXiyOEBp		MVvt[YRq[XSnczDk[U1xcG:\|cHjvdplt[XSrb36gc4YhW1SDVEOgZ49zemWuYYTl[EB4cXSqIFjTVFcxKGGwZDDIV2YzKHKnZIXjeIlwdg>?	NGCyOokzPjF6NEm5PS=>
BC3	M2XQe2Z2dmO2aX;uJGF{e2G7	NF3rcpMyODEkgJpCuW0>	Mli3NlQhcA>?		Mn;ybY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMh\my3eNMg	NWe1VIE{OjZzOES5PVk>
BCBL1	MnfJSpVv[3Srb36gRZN{[Xl?	MmjJNVAx6oDLwsXN	NVLqVWNWOjRiaB?=		NHPaWYFqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yCobIX4xsA>	NGnVVYgzPjF6NEm5PS=>
SK-MEL-28	M3;VUmZ2dmO2aX;uJGF{e2G7	NHG0UZQ2OC9zMEFihKnDvU1?	MnnWOFghcA>?	M{i5TWROW09?	NXPv[JNbemWmdXPld{Bidm:ra3nzJJJme2m\|dHHuZ4U>	MYOyOVIyPjV{Mh?=
MeWo	NHnPcIdHfW6ldHnvckBCe3OjeR?=	NF\iU2Y2OC9zMEFihKnDvU1?	NU\pZ5dkPDhiaB?=	Mk\1SG1UVw>?	NUXTR\|I6emWmdXPld{Bidm:ra3nzJJJme2m\|dHHuZ4U>	NF\2Z4szPTJzNkWyNi=>
SK-MEL-5	MUfGeY5kfGmxbjDBd5NigQ>?	NVqx[3NFPTBxMUCw5qCKyrWP	M3nEVlQ5KGh?	Mlq2SG1UVw>?	NV;jZm5oemWmdXPld{Bidm:ra3nzJJJme2m\|dHHuZ4U>	M4f1[lI2OjF4NUKy
SK-MEL-2	NUfFNYVDTnWwY4Tpc44hSXO\|YYm=	MV61NE8yODEkgJpCuW0>	MYi0PEBp	NEjISlRFVVOR	NVPjfYkzemWmdXPld{Bidm:ra3nzJJJme2m\|dHHuZ4U>	MVuyOVIyPjV{Mh?=
B16-F0	NUXWc5VzTnWwY4Tpc44hSXO\|YYm=	NEXQOWY2OC9zMEFihKnDvU1?	NVjReok{PDhiaB?=	NGHSZY5FVVOR	M2rscJJm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl	NYLqeXdyOjV{MU[1NlI>
TRPM2/HEK	MmfiSpVv[3Srb36gRZN{[Xl?	NU[zcFJ2OC5z4pETNlXDqML3TR?=	NE\yUIoyPcLibXnu	M2XFR2ROW09?	MmXidoVlfWOnczDINm8zNWmwZIXj[YQhS2F{K3nuZ5Jm[XOnIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{LDDhcoQhfGinIFnDOVDDqH[jbIXlJJdieyBzLkhCpOK2VQ>?	NWfMclBEOjVzN{m1O\|Q>
U937	MoThSpVv[3Srb36gRZN{[Xl?	NHHrenQxNjIkgKOyOeKhyrWP	M2CzUlE2yqCvaX6=	NHXXXG9FVVOR	NVzNV5VJemWmdXPld{BJOk9{LXnu[JVk\WRiQ3GyL4lv[3KnYYPlJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyMEBidmRidHjlJGlEPTEEoI\hcJVmKHejczCwMlTDqML3TR?=	MUSyOVE4QTV5NB?=
TRPM2/HEK	NXu1dWF[TnWwY4Tpc44hSXO\|YYm=	MmWwNVDDqML3TR?=	NI\LT3Q1OMLibXnu	NXLJUo9mTE2VTx?=	MVHy[YR2[2W\|IGTSVG0zKGGldHn2ZZRqd25iZY\lckBifCCqaXfoJINwdmOnboTyZZRqd26\|IH;mJGgzVzJ?	NX7jNpZXOjVzN{m1O\|Q>
GL37	NWT0PXpXS2WubDDWbYFjcWyrdImgRZN{[Xl?	NELCeIwxNTFywrFCuW0>	NVr3dI5vPDhiaB?=		M{n2e5N2eHC{ZYPz[ZMhVGFiZYjwdoV{e2mxbh?=	MYiyOFk6QTZ3Nx?=
NRK-52E	M{\SUmZ2dmO2aX;uJGF{e2G7	MnLRNeKhyrWP	NE\qR2YyOCCvaX6=		NX;1fGJ1[myxY3vzJJRp\SC\|dHnteYxifG:{eTDl[oZm[3Rib3[gRY5oKEmLIH;uJHBigC1{IHX4dJJme3Orb39CpC=>	MY[yOFcyODR{Mx?=
NRK-52E	M37DXWZ2dmO2aX;uJGF{e2G7	NFm3WHcyyqEEtV2=	MVyxNEBucW5?		MWnicI9kc3NiQX7nJGlKKGmwZIXj[YQhS0R{NDDlfJBz\XO\|aX;u	NXnPS492OjR5MUC0NlM>
HSC	M374bWZ2dmO2aX;uJGF{e2G7	NEP3UWEzOCEQvF2=	Ml3iNUBp		NWrhPZRs[WK{b3fheIV{KHSqZTDkbYZn\XKnboTpZYwh\W[oZXP0d{Bw\iCuZYD0bY4hd3JiQVfFdy=>	NFizTJczPDZzNEG5PS=>
EJ	NELH[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DNUlUxNzhyIN88US=>	NGPGfIYzPC92OD:3NkBp		M2LWeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	Mn7VNlQ2QDdyNEm=
EJ	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXK1NE85OCEQvF2=	Ml60OFghcA>?		MWrjZZV{\XNiUz3wbIF{\SCjcoLld5Q>	NYnHW3hZOjR3OEewOFk>
EJ	M3\DUWZ2dmO2aX;uJGF{e2G7	MkTVOVAwQDBizszN	M1rsUlQ5KGh?		NXPo[2Vm\G:5boLl[5Vt[XSnczDjMW16[yxiY4njcIlvTDFuIIP1dpZqfmmwIHHu[EBXTUeIIHX4dJJme3Orb37z	MXuyOFU5PzB2OR?=
HepG2	NGrFZm5HfW6ldHnvckBCe3OjeR?=	MWm1NE02ODBizszN	NVnkRW5UPjEEoH3pci=>		MlnEbY5pcWKrdIOgeIhmKEmOLU[tbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gV3RCXDFiKGT5dlcxPSliYX7kJHNVSVR\|IDjUfZI4ODVrIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NXywSGhUOjR{NEKwOFY>
SGC7901	MkfLR4VtdCCYaXHibYxqfHliQYPzZZk>	MmPyNE0yODBizszN	MmfHNlQwPDhxN{KgbC=>		MYjjZZV{\XNiYTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh\G:\|ZT3k[ZBmdmSnboTsfUBjfXRibn;0JJRqdWVvZHXw[Y5l\W62bIm=	MX2yOFE2OTJ3NR?=
AGS	MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NEf6cm8xNTFyMDFOwG0>	Mk\mNlQwPDhxN{KgbC=>		MmrOZ4F2e2W\|IHGgd4lodmmoaXPhcpQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJkh[nW2IH7veEB1cW2nLXTldIVv\GWwdHz5	MlXnNlQyPTF{NUW=
SGC7901	NX;IOm9xTnWwY4Tpc44hSXO\|YYm=	MXK1NEDPxE1?	NIHBTIIzPC92OD:3NkBp		NFnxNGJ1cGVibHX2[Yx{KG:oIIDKRWszKGKnZ3HuJJRwKGSnY3zpcoUh[XRiMkSgbJItKGGwZDDy[YJwfW6mZXSgZZQhPzJiaINCpC=>	NVvQdnY1OjRzNUGyOVU>
AGS	NIDhSZRHfW6ldHnvckBCe3OjeR?=	NYT1O3pQPTBizszN	NX\HOIZnOjRxNEivO\|IhcA>?		Mme2eIhmKGyndnXsd{Bw\iCySlHLNkBj\WejbjD0c{Bl\WOuaX7lJIF1KDJ2IHjyMEBidmRicnXic5Vv\GWmIHH0JFczKGi{wrC=	MU[yOFE2OTJ3NR?=
SGC7901	NETyZ2RHfW6ldHnvckBCe3OjeR?=	NGHVTHY2OCEQvF2=	NIHnOpYzPC92OD:3NkBp		NV7EWXgzfGinIHP5eI9xdGG\|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:\|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC\|dHHyeIVlKHSxIILlZo92dmRiYYSgO\|IhcHJ?	MV:yOFE2OTJ3NR?=
AGS	MknVSpVv[3Srb36gRZN{[Xl?	MVm1NEDPxE1?	NGHlOG4zPC92OD:3NkBp		NYX3R4N[fGinIHP5eI9xdGG\|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:\|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC\|dHHyeIVlKHSxIILlZo92dmRiYYSgO\|IhcHJ?	NWeyd4lyOjRzNUGyOVU>
MC3T3-E1	NXj6PVYxTnWwY4Tpc44hSXO\|YYm=	M4D5NlUxKM7:TR?=	MnHIOEBp		MkPRbY5pcWKrdIOgTHNGNWmwZIXj[YQhSk2SNzDhcoQhT0iUIIDyc5RmcW5iZYjwdoV{e2mxbtMg	NFnRfGYzOzh5N{ezOC=>
7TD1-DXM	NEfzV\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTkbHdOOTBizszN	MkfVO\|IhcA>?	NITxTIpFVVOR	MkTjbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NXzPe2VzOjN6N{GxOVk>
7TD1-WD-90	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmj5NVAh\|ryP	M3KyU\|czKGh?	MYrEUXNQ	NV;TWow4cW6qaXLpeJMh[2WubDDndo94fGh?	NGG1OXAzOzh5MUG1PS=>
7TD1-DXM	MnT0RZBweHSxc3nzJGF{e2G7	NVvCWJhJPTBizszN	NV[5[2tNPDhiaB?=	NEnKOWZFVVOR	MXfpcoR2[2W\|IHHwc5B1d3Orcx?=	MlXVNlM5PzFzNUm=
7TD1-WD-90	Mm\0RZBweHSxc3nzJGF{e2G7	NWrCSGQ6PTBizszN	M17xNFQ5KGh?	MUDEUXNQ	M4ezeolv\HWlZYOgZZBweHSxc3nz	MmO1NlM5PzFzNUm=
7TD1-WD-90	MorKSpVv[3Srb36gRZN{[Xl?	NEnBWlE2OCEQvF2=	MmPQOkBp	NG\YXVRFVVOR	NY\3WllHe2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqDS{KgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCVVFHUNy=>	MYGyN\|g4OTF3OR?=
HepG2	MlrwSpVv[3Srb36gRZN{[Xl?	Mn:yNVAxKM7:TR?=	MWGxNk8zPCCq		MYDpcohq[mm2czDTWGFVOyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44>	NW\RTopOOjN6M{[0NFA>
RAW264.7	MWPGeY5kfGmxbjDBd5NigQ>?	NVu4dZg5PTEEoN88UeKh	M4\oVFI1NzR6IHi=		MmTvd5VxeHKnc4Pld{BTSU6NTD3pcoR2[2WmIH;zeIVw[2yjc4Tv[4Vv\XOrcx?=	MU[yN\|Y3PTBzOB?=
RAW264.7	NHGwNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MViwMVUxyqEQvF5CpC=>	MoXDOFjDqGh?		MnPObY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZT3k[ZBmdmSnboTsfS=>	MUKyN\|Y3PTBzOB?=
RAW264.7	M1fke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWS2VVVpOC13MNMg{txOyqB?	MYO0POKhcA>?		MWrjZZV{\XNiYX6gZZJz\XO2IH;mJHJCXzJ4ND63JINmdGy\|IHH0JJRp\SCJMD;HNUBxcGG\|ZTDv[kB1cGViY3XscEBkgWOuZR?=	NWjBNG9EOjN4NkWwNVg>
RAW264.7	MYLGeY5kfGmxbjDBd5NigQ>?	M4\KXVUxyqEQvF2=	NGrnOI0zPC92ODDo		Mn;nbY5pcWKrdIOgVmFPU0xvaX7keYNm\CCQRlHUZ\|Eh\XiycnXzd4lwdiCjbnSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNmejd{N2PURXQ{	NWP5PJFMOjN4NkWwNVg>
A549	Ml7zSpVv[3Srb36gRZN{[Xl?	MVGyNE81OCEQvF2=	NIXBN5AzOCCq		M2PTfVIxKM7:TTDBS\|Q6OCC\|dYDwdoV{e2W\|IITo[UBz[WSrYYTpc44ucW6mdXPl[EBqdn[jc3nvckBw\iCDNUS5JINmdGy\|	M3G2UlI{PjJyMUmx
A549	Mn36SpVv[3Srb36gRZN{[Xl?	NWXCe\|R{OTBxMkCvOFAh\|ryP	NYjwPHJLOjRiaB?=		NF;YbJl{fXCycnXzd4V{KHSqZTDyZYRq[XSrb36tbY5lfWOnZDDlcIV3[XSrb36gc4YhXkWJRtMg	MXmyN\|YzODF7MR?=
HUVECs	MmToR4VtdCCYaXHibYxqfHliQYPzZZk>	MUGyNEDDvU1?	M3G0OFQhcA>?		M3;zZoF1fGWwdXH0[ZMhUDKRMj3pcoR2[2WmIHPlcIwhe2i{aX7rZYdmKGGwZDDpcZBzd3[nZDD0bIUh[XS2YXPocYVvfCC{YYTlJI9nKHSqZTDj[Yxtew>?	M3:4SFI{PDh\|OUS2
HUVECs	NFHFV\|JCeG:ydH;zbZMhSXO\|YYm=	NIK2XYQzOCEEtV2=	NH7wUVc1KGh?		NHjtS4x{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUh[2WubDDhdI9xfG:2aXOgbY5l\Xh?	NWPGRnJyOjN2OEO5OFY>
BV-2	M2H3PWZ2dmO2aX;uJGF{e2G7	NF;RfG8zOCEEtV2=	MV:xOkBp		NYnpNWJOcW6qaXLpeJMhVFCVLXnu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJJdqfGhiYXztc5N1KGOxbYDs[ZRmdHliZHntbY5qe2inZDDpUm9UKGW6cILld5Nqd25?	M1X1PVI{OjN4M{ew
NRK-52E	M4rzfWZ2dmO2aX;uJGF{e2G7	NXW5XoYyPcLizszN	MVGzNOKhdWmw		NX\vXHlS[XS2ZX71ZZRmeyCDbnetLFHjiJN5KT3pcohq[mm2ZXSgWGdHNc7{MTDtVm5CKGG2IEG2xsBpyqB?	NUThUG16OjNzN{S3OVc>
SW620	NWOxd4s3TnWwY4Tpc44hSXO\|YYm=	MWmyNEDDvU1?	Mor5NU83KGh?		NETMN\|hqdmirYnn0d{BxNVOWQWSzJIFkfGm4YYTpc44>	MmnpNlMyOTB4MkW=
RPE	NI\3bIFHfW6ldHnvckBCe3OjeR?=	NXL3dIlQOzBiwsXNxsA>	NVjuflNWOyCq		M1ziTolvcGmkaYTzJJRp\SCrbnT1Z5Rqd25ib3[gdE1UXEGWMzDlfJBz\XO\|aX;u	NXLINIFIOjNyOUSwOlc>
SW1116	NEDocVlHfW6ldHnvckBCe3OjeR?=	NW\reFhrOTByINM1UeKh	NEfZeYwzPC92OD:3NkBp		NVv1bYRx\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKEqDS{KgZY5lKHCMQVuyJJRqdWVvZHXw[Y5l\W62bIm=	Mk\ONlIxPTB5OUC=
HT29	MonZSpVv[3Srb36gRZN{[Xl?	NYHGeYY1OTByINM1UeKh	NH\5Z4szPC92OD:3NkBp		MWrk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gTmFMOiCjbnSgdGpCUzJidHnt[U1l\XCnbnTlcpRtgQ>?	M3fxVlIzODVyN{mw
SW1116	MX3GeY5kfGmxbjDBd5NigQ>?	Mn3SNVAxKML3TdMg	M{TTb\|I1NzR6L{eyJIg>		NE\Lcm9l\WO{ZXHz[ZMhfGinIIDTWGFVOyCuZY\lcJMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>?	MYmyNlA2ODd7MB?=
HT29	M2fkdWZ2dmO2aX;uJGF{e2G7	M3GyOlExOCEEtV5CpC=>	MoTRNlQwPDhxN{KgbC=>		NGiyVYFl\WO{ZXHz[ZMhfGinIIDTWGFVOyCuZY\lcJMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>?	M4ez[lIzODVyN{mw
ARPE-19	NVXPc21TTnWwY4Tpc44hSXO\|YYm=	MUG1xsDPxE1?	M{HEVlMxyqCvaX6=		M4jxW4lvcGmkaYTzJGpCUzJicHjvd5Bpd3KrbHH0bY9v	M4DDSlIyPjJyOU[z
HSC-T6	NFu2W3ZCeG:ydH;zbZMhSXO\|YYm=	NXW1SJdzOTEEoN88US=>	Mn60NuKhcMLi		MnzlbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCxZjDIV2MuXDZiY3XscJMhcW6mdXPl[EBjgSCFRFW=	Mn24NlE{QTZ7OUi=
HSC-T6	NGTMUIVHfW6ldHnvckBCe3OjeR?=	NEj3eVEyOMLizszN	Ml7MNuKhcMLi		M{CxVYlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wczDv[kBxYS2VVFHUNUBidmRiQnHkJIlv\HWlZXSgZpkhS0SH	NXzsTldjOjF\|OU[5PVg>
Hep-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkP3NlUuOTByIN88US=>	NVnjc41COjRxNEivO\|IhcA>?		M37HZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MkLBNlE{ODl2OEG=
Hep-2	NVPCc\|l2SXCxcITvd4l{KEG\|c3H5	NWTPdoJiPTBizszN	NX\aOmpDOjRxNEivO\|IhcA>?		NIfRSFJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IITpcYUh\GWyZX7k[Y51dHl?	M3WzcFIyOzB7NEix
Hep-2	MmXwSpVv[3Srb36gRZN{[Xl?	M2HvVVUxKM7:TR?=	MXWyOE81QC95MjDo		MUjpcohq[mm2czDHNUB1dyCVIHPlcIwh[3mlbHWgeJJidnOrdHnvckBidmRiaX7keYNmeyCJMTDj[YxtKGO7Y3zlJIFzemW\|dB?=	M1i1flIyOzB7NEix
Hep-2	NVHBWo4{TnWwY4Tpc44hSXO\|YYm=	Mk\3OVAh\|ryP	M3\WVVI1NzR6L{eyJIg>		NG[3UmJld3ewcnXneYxifGW\|IITo[UBUXEGWMzygdE1UXEGWMzDhcoQhe3W{dnn2bY4heHKxdHXpckBt\X[nbIO=	NGnRSWQzOTNyOUS4NS=>
KF8	MYnGeY5kfGmxbjDBd5NigQ>?	NIX1bnIyOMLizszNxsA>	M3vncVHDqGh?	NX\Ee5ZrTE2VT9Mg	NFHieYZqdmirYnn0d{BKVC1\|Mz3pcoR2[2WmIF7GMe67SiCjY4TpeoF1cW:w	M4TPUlIxQTRyMES1
KF8	MmXQSpVv[3Srb36gRZN{[Xl?	NVTiblc2OTEEoN88UeKh	MV6xxsBpyqB?	NV3Me2RpTE2VT9Mg	NVH6UZlucW6qaXLpeJMhUUxvM{OtbY5lfWOnZDDJ{tpD\|rFiZHXndoFl[XSrb36gZY5lKE6ILd86RkBi[3SrdnH0bY9v	NHnRWYQzODl2MEC0OS=>
HEL	NGjDc2tHfW6ldHnvckBCe3OjeR?=	Mk\lNVAxyqEQvF2=	MnLrNVIuPzJiaB?=		NHXVUllqdmirYnn0d{B1cGVibHX2[Ywhd2ZicD3KRWszNCCMQVuy	NGG2dHYzODZ{MUC2NS=>
HEL	NXfp[44{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDUS5psOTBywrFOwG0>	M2jnTlAuPSCm		M4rwXZJm\HWlZYOg[5Jwf3SqIH;mJGpCUzKYNkG3Sk1mgHC{ZYPzbY5oKEiHTDDj[Yxtew>?	Mn\BNlA3OjFyNkG=
A-172	MUHGeY5kfGmxbjDBd5NigQ>?	M3\ENVUxNzFyMNMg{txO	MVS0PEBp		NU\q[Fc5emWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	Mn73NlA2QDl3MkW=
MZ-18	MU\GeY5kfGmxbjDBd5NigQ>?	MXi1NE8yODEEoN88US=>	NWe1bmg1PDhiaB?=		NYL4fotZemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NFm5PFczODV6OUWyOS=>
MZ-54	MYHGeY5kfGmxbjDBd5NigQ>?	NUfnVFJjPTBxMUCwxsDPxE1?	NUnJZYxMPDhiaB?=		NWfhdZZIemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NU\4[G9YOjB3OEm1NlU>
MZ-256	M{TUWWZ2dmO2aX;uJGF{e2G7	NHfmRYQ2OC9zMEFCpO69VQ>?	NV31OIpNPDhiaB?=		NXTlWmtTemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NVnTcWl2OjB3OEm1NlU>
MZ-304	MmHzSpVv[3Srb36gRZN{[Xl?	MnXJOVAwOTBywrFOwG0>	M1ricFQ5KGh?		MmnmdoVlfWOnczD0bIUhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBUXEGWMzDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MmXENlA2QDl3MkW=
A-172	NEfUSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LZV\|UxNzFyMNMg{txO	M3XZOlQ5KGh?		MU\s[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh?	MXiyNFU5QTV{NR?=
MZ-18	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;NOVAwOTBywrFOwG0>	M4XMVlQ5KGh?		MYXs[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh?	Mln6NlA2QDl3MkW=
MZ-54	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLHblM2OC9zMEFCpO69VQ>?	MXK0PEBp		M{TuNIxm[WS\|IITvJIEhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;2[ZIh[SC2aX3lJJBmemmxZDDv[kA1QMLiaB?=	NGjxVZYzODV6OUWyOS=>
MZ-256	NGXG[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HNTVUxNzFyMNMg{txO	NHfLVJc1QCCq		NVXKXVNZdGWjZIOgeI8h[SC\|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo	Mn3wNlA2QDl3MkW=
MZ-304	NUCwS\|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHzWYo2OC9zMEFCpO69VQ>?	MX[0PEBp		NWf3NFMxdGWjZIOgeI8h[SC\|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo	M3W5c\|IxPTh7NUK1
A-172	NF3rNIxHfW6ldHnvckBCe3OjeR?=	M4DCZ\|UxNzFyMNMg{txO	M3[3bFQ5KGh?		NWnJSoJxcW6qaXLpeJMhdWmpcnH0bY9v	MlPYNlA2QDl3MkW=
MZ-18	NInIPZpHfW6ldHnvckBCe3OjeR?=	MUm1NE8yODEEoN88US=>	NXzQeXBlPDhiaB?=		MlrUbY5pcWKrdIOgcYloemG2aX;u	NFXvV2gzODV6OUWyOS=>
MZ-54	MlyySpVv[3Srb36gRZN{[Xl?	NWrtbIJtPTBxMUCwxsDPxE1?	Mkn1OFghcA>?		NGfCbIRqdmirYnn0d{BucWe{YYTpc44>	M3L6VFIxPTh7NUK1
MZ-256	MWXGeY5kfGmxbjDBd5NigQ>?	NWXoeY5NPTBxMUCwxsDPxE1?	NUjrWmh7PDhiaB?=		MX;pcohq[mm2czDtbYdz[XSrb36=	MXeyNFU5QTV{NR?=
MZ-304	Mn3oSpVv[3Srb36gRZN{[Xl?	M1j6O\|UxNzFyMNMg{txO	MV[0PEBp		MnzJbY5pcWKrdIOgcYloemG2aX;u	MnfCNlA2QDl3MkW=
A-172	MXXGeY5kfGmxbjDBd5NigQ>?	NVTwUnBNOTBywrFOwG0>	NXfke3JqPDhiaB?=		NYPXcIRNcW6qaXLpeJMhcW64YYPpc44>	NEDTVW0zODV6OUWyOS=>
MZ-18	NEH0cYZHfW6ldHnvckBCe3OjeR?=	MYCxNFDDqM7:TR?=	MXi0PEBp		NGTzfm5qdmirYnn0d{Bqdn[jc3nvci=>	Mn\zNlA2QDl3MkW=
MZ-54	NIP1dIFHfW6ldHnvckBCe3OjeR?=	NIn0PYsyODEEoN88US=>	NXHNeWtUPDhiaB?=		M1nsO4lvcGmkaYTzJIlvfmG\|aX;u	NIPp[2czODV6OUWyOS=>
MZ-256	MXHGeY5kfGmxbjDBd5NigQ>?	MkHINVAxyqEQvF2=	Mo\QOFghcA>?		M4XO[IlvcGmkaYTzJIlvfmG\|aX;u	NYT1OGpnOjB3OEm1NlU>
MZ-304	NVnzTnE5TnWwY4Tpc44hSXO\|YYm=	NXr2W\|N2OTBywrFOwG0>	NYfYdZo6PDhiaB?=		Mny1bY5pcWKrdIOgbY53[XOrb36=	MYeyNFU5QTV{NR?=
A-172	NXS1bFkxTnWwY4Tpc44hSXO\|YYm=	MWm1NE8yODEEoN88US=>	M2X5flQ5KGh?		MV\y[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	NXfCVJpJOjB3OEm1NlU>
MZ-18	NUD5WXpxTnWwY4Tpc44hSXO\|YYm=	MlLJOVAwOTBywrFOwG0>	MkHkOFghcA>?		MkLVdoVlfWOnczD0doFve2O{aYD0bY9vKG:oIF3NVEBo\W6nczDhcoQhemWmdXPld{Bmdnq7bXH0bYMh[WO2aY\peJkhd2ZiTV3Qdy=>	MmDnNlA2QDl3MkW=
MZ-54	NGHsVYZHfW6ldHnvckBCe3OjeR?=	MoXvOVAwOTBywrFOwG0>	Mnq1OFghcA>?		MV3y[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	NWf1Rm5UOjB3OEm1NlU>
MZ-256	M4jabGZ2dmO2aX;uJGF{e2G7	MknNOVAwOTBywrFOwG0>	Mn7DOFghcA>?		NUXIbIF{emWmdXPld{B1emGwc3PybZB1cW:wIH;mJG1OWCCpZX7ld{BidmRicnXkeYNmeyCnbor5cYF1cWNiYXP0bZZqfHlib3[gUW1Rew>?	MmXXNlA2QDl3MkW=
MZ-304	NH61W4pHfW6ldHnvckBCe3OjeR?=	MkK1OVAwOTBywrFOwG0>	M4G5NFQ5KGh?		NV3zW4tnemWmdXPld{B1emGwc3PybZB1cW:wIH;mJG1OWCCpZX7ld{BidmRicnXkeYNmeyCnbor5cYF1cWNiYXP0bZZqfHlib3[gUW1Rew>?	MXuyNFU5QTV{NR?=
SW1990	NWO1emt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDHOHVTOjBizszN	MnjtNlQwPDhxN{KgbC=>		NVXuRYcycW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>?	MWqyNFQ5Ojh3OB?=
SW1990	MnLZSpVv[3Srb36gRZN{[Xl?	M{XLelIxKM7:TR?=	NEjvfXAzPCCq		M2fJcIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBOVVBvMjDhcoQhXkWJRjDtVm5Cew>?	MUGyNFQ5Ojh3OB?=
SW1990	MVTGeY5kfGmxbjDBd5NigQ>?	Ml7oNlAh\|ryP	NESzNHEzPCCq		NUTy[pV4\GWlcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YheC2VdHH0N{BmgHC{ZYPzbY9v	MmPGNlA1QDJ6NUi=
SW1990	M2fEcGlvfmG\|aX;uJGF{e2G7	NHzFRVYzOCEQvF2=	NHPRd2szPCCq		MlLudoVlfWOnczDpcpZie2mxbjDv[kBUXzF7OUCgZ4VtdHQEoB?=	NWL5dGl5OjB2OEK4OVg>
THP1	MmPySpVv[3Srb36gRZN{[Xl?	M2jPPFExKHWP	NX;5fVhxOzBibXnuxsA>		NEWxXpZqdmirYnn0d{BUXEGWMzD0fZJwe2mwZTDwbI9{eGixconsZZRqd25iYomgc5ZmeiB4MDW=	MWGyNFM6OzZ7MB?=
BMMC	NHz5dolHfW6ldHnvckBCe3OjeR?=	NVnxTWJtOC1zMDFOwG0>	MonHNVXDqG2rbh?=		M{PJeolvcGmkaYTzJGxVSzUEoILlcIVie2ViaX6gZUBld3OnLXTldIVv\GWwdDDmZZNpcW:wIIfpeIghdmWjcjDjc41xdGW2ZTDpcohq[mm2aX;uJIF1KGOxbnPlcpRz[XSrb37zJQKqxjFywrFOwG0>	Mln4NVk5OzV6NEW=
A549	NUTtdVlrTnWwY4Tpc44hSXO\|YYm=	NHfRWnAyPSEQvH2=	NH3NeWUyKGh?		NHy1XWhqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKG:wIIT5do9{cW6nIEewNUB4[XNiZHX0[YN1\WRiMUWgcYlvKGGodHXyJHNRTSCEIITy[YF1dWWwdB?=	MUmxPVgxOTZ4NR?=
OVCAR-3	M{nRZ2Z2dmO2aX;uJGF{e2G7	NXv4SJlGOTBidV2=	NGrNOlUyKGh?		NYnTTFVkcW6qaXLpeJMhVFCDLXnu[JVk\WRiU2TBWFMheGixc4Doc5J6dGG2aX;u	M3fqPFE6PjR5M{[z
PA-1	NHW2UHBHfW6ldHnvckBCe3OjeR?=	NVnJepd2OTBidV2=	M1HBUVEhcA>?		M12yfIlvcGmkaYTzJGxRSS2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?=	MXOxPVY1PzN4Mx?=
OVCAR-3	NF7NTlhHfW6ldHnvckBCe3OjeR?=	NXjQ[XZHOTBidV2=	MkXDNUBp		MlnnbY5pcWKrdIOgJGxRSS2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxibX;0bYxqfHl?	NXLHRm5[OTl4NEezOlM>
PA-1	MUXGeY5kfGmxbjDBd5NigQ>?	M2DtblExKHWP	NVe1TpVQOSCq		NXe1U5BkcW6qaXLpeJMhKEySQT3pcoR2[2WmIH;2ZZJq[W5iY3HuZ4VzKGOnbHygcY91cWyrdIm=	MUKxPVY1PzN4Mx?=
Jurkat	NIfTVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{X2UVUxKM7:TR?=	MkfpNlQwPDhxN{KgbC=>		MWrlcohidmOnczDUVmFKVC2rbnT1Z4V{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36=	M1jQUlE6PTZ2OEmx
SUPT1	M{XlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LwWlUxKM7:TR?=	M2TyflI1NzR6L{eyJIg>		M{HyZYVvcGGwY3XzJHRTSUmOLXnu[JVk\XNiY3XscEBoem:5dHigbY5pcWKrdHnvci=>	NHfzVY8yQTV4NEi5NS=>
Jurkat	M33vOmFxd3C2b4Ppd{BCe3OjeR?=	NVWzVotoPTBizszN	MXuyOE81QCCq		MnLv[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIFxd3C2b4Ppdy=>	NH;3NWUyQTV4NEi5NS=>
SUPT1	M3v1fGFxd3C2b4Ppd{BCe3OjeR?=	MmniOVAh\|ryP	NWfSfI1JOjRxNEigbC=>		NIHobFNmdmijbnPld{BVWkGLTD3pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MnXzNVk2PjR6OUG=

... Click to View More Cell Line Experimental Data

In vivo

Administration of AG-490 drastically reduces the numbers of CD45⁺ and HLA-DR⁺ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. ^[2] In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. ^[6] Consistent with the in vitro blocking of JAK2 V617F mutant activity, AG-490 treatment at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. ^[8] Combined therapy with AG-490 and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. ^[6]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase autophosphorylation: AG-490 is dissolved in DMSO 10%-H₂O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M₈Ac₂, 2 mM MnCl₂, 1 mM NaVO₃, 1 μM ATP, and 1 μCi[γ-³²P]ATP, final concentrations) and increasing concentrations of AG-490 (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of AG-490 (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
Cell Research: ^[2]	- Collapse Cell lines: Pre-B ALL Concentrations: Dissolved in DMSO, final concentrations ~ 50 μM Incubation Time: 16 hours Method: Cells are exposed to different concentrations of AG-490 for 16 hours. For the determination of cell proliferation, [³H]tymidine (1 μCi) is added 6 hours or more before the cultures are terminated. Cells are then collected and samples counted in a liquid scintillation counter. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: SCID mice intravenously injected with ALL cells Dosages: 0.85 mg + 0.5 mg daily Administration: Continuous pump infusion supplemented with daily intraperitoneal injections (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	58 mg/mL (197.07 mM)
	Water	Insoluble
	Ethanol	'6 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG300+5% Tween80+50% ddH2O For best results, use promptly after mixing.	6.25 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AG-490 (Tyrphostin B42) SDF

Molecular Weight	294.30
Formula	C₁₇H₁₄N₂O₃
CAS No.	133550-30-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Zinc02557947
Smiles	C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to know whether AG490 (S1143) goes to CNS through BBB, or not?
Answer:
AG-490 can go through the BBB. You can see this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

AG-490 (Tyrphostin B42)